[On the immunologic sensitizability of tumor patients].
D000230:Adenocarcinoma / Q000276:immunology; D002293:Adenocarcinoma, Scirrhous / Q000276:immunology; D000368:Aged; D000818:Animals; D000937:Antigen-Antibody Reactions; D001943:Breast Neoplasms / Q000276:immunology; D001984:Bronchial Neoplasms / Q000276:immunology; D002277:Carcinoma / Q000276:immunology; D002294:Carcinoma, Squamous Cell; D005260:Female; D005770:Gastrointestinal Neoplasms / Q000276:immunology; D005833:Genital Neoplasms, Female / Q000276:immunology; D006736:Horses; D006801:Humans; D006967:Hypersensitivity; D006968:Hypersensitivity, Delayed; D006969:Hypersensitivity, Immediate; D007106:Immune Sera; D008297:Male; D008875:Middle Aged; D012157:Mononuclear Phagocyte System / Q000276:immunology; D009169:Mycobacterium tuberculosis; D009369:Neoplasms / Q000276:immunology*; D011471:Prostatic Neoplasms / Q000276:immunology; D014373:Tuberculin
D007106:Immune Sera; D014373:Tuberculin
Uber die Sensibilisierbarkeit von Tumorkranken.